Home Harmonization of growth hormone measurements with different immunoassays by data adjustment
Article
Licensed
Unlicensed Requires Authentication

Harmonization of growth hormone measurements with different immunoassays by data adjustment

  • Anne Müller , Markus Scholz , Oliver Blankenstein , Gerhard Binder , Roland Pfäffle , Antje Körner , Wieland Kiess , Annegret Heider , Martin Bidlingmaier , Joachim Thiery and Jürgen Kratzsch EMAIL logo
Published/Copyright: June 1, 2011

Abstract

Background: The aim of our study was to evaluate the between-assay variability of commercially available immunoassays for the measurement of human growth hormone (hGH). In addition, we asked whether the comparability of the diagnosis of childhood onset growth hormone deficiency could be improved by adjusting hGH results by statistical methods, such as linear regression, conversion factors, and quantile transformation.

Methods: In archived sera from 312 children and adolescents (age: 17 days–17 years) hGH values between 0.01 and 16.5 ng/mL were determined by using the following immunoassays: AutoDELFIA (PerkinElmer), BC-IRMA (Beckman-Coulter), ELISA (Mediagnost), IMMULITE 2000 (Siemens), iSYS (IDS), Liaison (DiaSorin), UniCel DxI 800 Access (BeckmanCoulter) and “In house”-RIA (Tübingen).

Results: The assays differed in median hGH concentrations by as much as 5.44 ng/mL (Immulite), and as little as 2.67 ng/mL (BC-IRMA). The mean difference between assays ranged from 0.35 to 2.71 ng/mL, whereas several samples displayed differences up to 11.4 ng/mL. The best correlation (r=0.992) was found between AutoDELFIA and Liasion, the lowest (r=0.864) was between an in-house RIA and iSYS. The between-assay CV (mean±SD) of values within the cut-off range was 24.3%±7.4%, resulting in an assay-dependent diagnosis of growth hormone deficiency (GHD) in more than 27% of patients. Yet, adjustment of this data by linear regression or a conversion factor reduced the CV below 14%, and the ratio of assay-dependent diagnoses below 8%. Using quantile transformation, the CV and ratio were reduced to 11.4% and <1%, respectively.

Conclusions: hGH measurements using different assays vary significantly. Linear regression, conversion factors, or particularly quantile transformation are useful tools to improve comparability in the diagnostic procedure for the confirmation of GHD in childhood and adolescence.


Corresponding author: Prof. Dr. rer. nat. Jürgen Kratzsch, University of Leipzig, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Paul-List-Str. 13–15, 04103 Leipzig, Germany Phone: +49 341 97 222 41

Received: 2010-11-18
Accepted: 2011-3-6
Published Online: 2011-06-01
Published in Print: 2011-07-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Method comparison: where do we draw the line?
  3. Review
  4. Current role of liquid chromatography coupled to mass spectrometry in clinical toxicology screening methods
  5. Minireview
  6. Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications
  7. Opinion Paper
  8. Preanalytical quality improvement: from dream to reality
  9. Point
  10. Towards more complete specifications for acceptable analytical performance – a plea for error grid analysis
  11. Counterpoint
  12. Closing the brain-to-brain loop in laboratory testing
  13. General Clinical Chemistry and Laboratory Medicine
  14. Harmonization of growth hormone measurements with different immunoassays by data adjustment
  15. Comparison of the results from two different External Quality Assessment Schemes supports the utility of robust quality specifications
  16. High-throughput LC-MS/MS method for monitoring sirolimus and everolimus in the routine clinical laboratory
  17. Performance of the Roche Total Mycophenolic Acid® assay on the Cobas Integra 400®, Cobas 6000® and comparison to LC-MS/MS in liver transplant patients
  18. Diagnostic efficiency of truncated area under the curve from 0 to 2 h (AUC0–2) of mycophenolic acid in kidney transplant recipients receiving mycophenolate mofetil and concomitant tacrolimus
  19. Good performance of an immunoassay based method for nevirapine measurements in human breast milk
  20. Measurement of plasma amino acids by Ultraperformance® Liquid Chromatography
  21. Interchangeability of blood gas, electrolyte and metabolite results measured with point-of-care, blood gas and core laboratory analyzers
  22. Granularity Index of the SYSMEX XE-5000 hematology analyzer as a replacement for manual microscopy of toxic granulation neutrophils in patients with inflammatory diseases
  23. Direct chromogenic substrate immuno-capture activity assay for testing of factor VII-activating protease
  24. The antinuclear antibody assay: developing criteria for reflexive anti-dsDNA antibody testing in a laboratory setting
  25. A simple liquid chromatography-tandem mass spectrometry method for measuring metanephrine and normetanephrine in urine
  26. Monoclonal gammopathy missed by capillary zone electrophoresis
  27. Adaptation of the Diazyme Direct Enzymatic HbA1c Assay for a microplate reader at room temperature
  28. Validation and Outcome Studies
  29. Laboratory assessment of iron status in pregnancy
  30. Cardiovascular Diseases
  31. Blood cells characteristics as determinants of acute myocardial infarction
  32. No evidence for an association between the rs2824292 variant at chromosome 21q21 and ventricular fibrillation during acute myocardial infarction in a German population
  33. Letters to the Editor
  34. Letter to the Editor Reply: Statistical methods for assessment of added usefulness of new biomarkers
  35. Reply to Vavrova et al. Clin Chem Lab Med 2011;49:89–92
Downloaded on 27.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.201/html
Scroll to top button